Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects-Reference-Cited by-同舟云学术

Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects

Published:2006 Issue:8 Volume:45 Page:821-841
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clinical Pharmacokinetics

Author:

Khosravan Reza,Grabowski Brian A,Wu Jing-Tao,Joseph-Ridge Nancy,Vernillet Laurent

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference34 articles.

1. Incidence and Risk Factors for Gout in White Men

2. The Management of Gout

3. THE METABOLISM OF URIC ACID IN THE NORMAL AND GOUTY HUMAN STUDIED WITH THE AID OF ISOTOPIC URIC ACID

4. Gout: The last 50 years

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetic analysis of febuxostat with high focus on absorption kinetics and food effect;BMC Pharmacology and Toxicology;2024-08-26

2. Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study;Heart and Vessels;2024-08-19

3. Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout;Journal of Medicinal Chemistry;2024-08-07

4. <i>In-vitro</i> dissolution profiles comparison for various drugs with active ingredient Febuxostat commercially available on the Russian market;Pharmacokinetics and Pharmacodynamics;2024-01-22

5. Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application;Life;2023-11-11